Your session is about to expire
← Back to Search
ANGPTL3 Variant Effects for Low Cholesterol
N/A
Recruiting
Led By Marina Cuchel, MD, PhD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Carrying genetic variants in the gene encoding for ANGPTL3
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 13 weeks
Awards & highlights
Study Summary
This trial looks at the role of a protein called ANGPTL3 on metabolism. They will explore how this protein affects both lipid and glucose metabolism.
Who is the study for?
This trial is for adults who either carry genetic variants in the ANGPTL3 gene or are unaffected controls matched by age, race, and gender. Participants must be willing to follow study procedures and provide informed consent. It excludes those with a history of significant health issues like drug abuse, cancer, liver or kidney disease, uncontrolled hypertension or diabetes, recent major surgery, anemia, or those on certain medications.Check my eligibility
What is being tested?
The trial aims to understand how the protein ANGPTL3 affects lipid (fat) metabolism and glucose (sugar) metabolism in humans. Participants will undergo tests including a kinetics test to measure fat processing speed after eating fats; an oral fat tolerance test; and an oral glucose tolerance test to see how well their body handles sugar.See study design
What are the potential side effects?
Since this trial involves diagnostic tests rather than medication trials, side effects may include discomfort from blood draws or potential reactions from consuming high-fat or high-sugar substances during the tolerance tests.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I carry a genetic variant in the ANGPTL3 gene.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 13 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 13 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The role of ANGPTL3 on lipid metabolism.
The role of ANPTL3 on fatty acids
The role of this protein on glucose metabolism.
Trial Design
2Treatment groups
Experimental Treatment
Group I: VariantExperimental Treatment1 Intervention
Volunteers with known ANGPTL3 variants
Group II: Non-variantExperimental Treatment1 Intervention
Healthy volunteers with no ANGPTL3 variants
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,005 Previous Clinical Trials
42,882,159 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,837 Previous Clinical Trials
47,851,544 Total Patients Enrolled
Marina Cuchel, MD, PhDPrincipal InvestigatorUniversity of Pennsylvania
10 Previous Clinical Trials
1,298 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My blood pressure is not higher than 160/100 mmHg.I match the age, race, and gender of the study's control group.I am not pregnant or nursing.I am not on any medication that could risk my safety or affect the study results.I have had an organ transplant.I have a history of liver disease or my liver tests are more than twice the normal limit.You have a history of excessive alcohol or drug use.I have had cancer other than skin cancer in the last 5 years.My diabetes is not under control.I have kidney disease or my kidney function is low.I have not had major surgery in the last 3 months.I am 18 years old or older.I carry a genetic variant in the ANGPTL3 gene.
Research Study Groups:
This trial has the following groups:- Group 1: Variant
- Group 2: Non-variant
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are research volunteers still being sought for this project?
"The listing on clinicaltrials.gov says that this research is still looking for subjects. The posting went up on December 1st, 2020, and the most recent update was on May 5th, 2022. So far, only 50 people have signed up at the one location."
Answered by AI
How many study participants are currently being treated with the trial medication?
"Precisely, the clinicaltrials.gov website has the latest information on this trial's status. The trial was posted on December 1st, 2020 and was updated on May 5th, 2022. The study is looking for 50 participants at a single site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger